Online citations, reference lists, and bibliographies.
← Back to Search

Recent Advances On The Development Of Pharmacotherapeutic Agents On The Basis Of Human Serum Albumin.

F. Liu, Jing Mu, B. Xing
Published 2015 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Human serum albumin (HSA), a major transport protein component in blood plasma, has been reported recently to play many important roles in pharmacotherapeutics development. Owing to its promising intrinsic binding capability of drug molecules, HSA offers favorable characteristics and can be directly used as its monomeric formula or can be fabricated into protein based nanoparticle platforms to realize the effective delivery of therapeutic molecules into targeted diseases areas. In addition, HSA can also serve as a protein stabilizer or environment-responsive moieties to hybridize with the functional materials including polymers or inorganic nanoparticles through the covalent reactions or electrostatic interactions, and can thus greatly alter the relevant biological distribution and pharmacokinetic behavior to improve their therapeutic efficacy. By right, extensive studies have been conducted to develop HSA-conjugated pharmacotherapeutic agents toward effective in vitro and in vivo diseases diagnosis and treatment. The current review gives an in-detail account of the latest progresses of HSA-based carriers as functional protein materials, mainly with respect to its conjugation types, formulation aspects, and importantly their promising applications towards enhanced drug delivery and medical diagnosis.
This paper references
10.1021/la301104a
Impact of the nanoparticle-protein corona on colloidal stability and protein structure.
J. Gebauer (2012)
10.1088/0957-4484/25/17/175702
Serum-stable quantum dot-protein hybrid nanocapsules for optical bio-imaging.
J. Y. Lee (2014)
10.1007/s00253-012-4569-z
Enzyme-catalyzed protein crosslinking
T. Heck (2012)
10.1039/c0ob00228c
pH-Sensitive, N-ethoxybenzylimidazole (NEBI) bifunctional crosslinkers enable triggered release of therapeutics from drug delivery carriers.
A. Luong (2010)
10.1021/tx5001317
Binding of human serum albumin to single-walled carbon nanotubes activated neutrophils to increase production of hypochlorous acid, the oxidant capable of degrading nanotubes.
Naihao Lu (2014)
10.1016/j.biomaterials.2014.06.013
Near-infrared dye bound albumin with separated imaging and therapy wavelength channels for imaging-guided photothermal therapy.
Q. Chen (2014)
10.7150/THNO/V01P0230
Photosensitizer-Conjugated Human Serum Albumin Nanoparticles for Effective Photodynamic Therapy
Hayoung Jeong (2011)
10.1002/CHIN.200232287
Dendritic Polymers in Biomedical Applications: From Potential to Clinical Use in Diagnostics and Therapy
Salah-Eddine Stiriba (2002)
10.1039/C0SM00412J
An overview of protein–polymer particles
C. Boyer (2011)
10.1371/journal.pone.0097565
Fetuin-A and Albumin Alter Cytotoxic Effects of Calcium Phosphate Nanoparticles on Human Vascular Smooth Muscle Cells
Yana Dautova (2014)
10.1023/A:1015396825274
Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin
Victor Tuan Giam Chuang (2004)
10.1186/1472-6750-12-68
Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion
M. Liu (2012)
Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
G. Hartung (1999)
10.1016/j.ddtec.2009.01.002
Intracellular delivery of protein and peptide therapeutics.
V. Torchilin (2008)
10.1007/978-1-60761-609-2_3
Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
K. Greish (2010)
10.3390/ijms12010334
The Role of Reactive-Oxygen-Species in Microbial Persistence and Inflammation
R. Spooner (2011)
10.3389/fimmu.2014.00561
Therapeutic Impact of Human Serum Albumin–Thioredoxin Fusion Protein on Influenza Virus-Induced Lung Injury Mice
R. Tanaka (2014)
10.1155/2012/686108
Cationic Albumin Nanoparticles for Enhanced Drug Delivery to Treat Breast Cancer: Preparation and In Vitro Assessment
S. Abbasi (2012)
10.1021/ac302417k
Human serum albumin stabilized gold nanoclusters as selective luminescent probes for Staphylococcus aureus and methicillin-resistant Staphylococcus aureus.
Po-Han Chan (2012)
10.1002/jps.23455
A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity.
A. Yuan (2013)
10.1016/j.ijpharm.2013.10.022
HSA nanocapsules functionalized with monoclonal antibodies for targeted drug delivery.
A. Rollett (2013)
10.1093/bioinformatics/btr284
Evaluation of drug-human serum albumin binding interactions with support vector machine aided online automated docking
F. Zsila (2011)
10.1021/nn405019v
Impact of protein modification on the protein corona on nanoparticles and nanoparticle-cell interactions.
Lennart Treuel (2014)
10.1016/j.jconrel.2011.07.041
Nuclear drug delivery for cancer chemotherapy.
M. Sui (2011)
10.1093/protein/gzt044
An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.
V. Berger (2013)
10.1016/j.tips.2011.09.001
Suppressing production of reactive oxygen species (ROS) for influenza A virus therapy.
R. Vlahos (2012)
10.5582/BST.2012.V6.2.81
N-terminal PEGylation of human serum albumin and investigation of its pharmacokinetics and pulmonary microvascular retention.
T. Zhao (2012)
10.1016/j.biomaterials.2013.11.001
Enzyme delivery using the 30Kc19 protein and human serum albumin nanoparticles.
Hong Jai Lee (2014)
10.1155/2014/180549
Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy
Warangkana Lohcharoenkal (2014)
10.1021/nn405830g
Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials.
Gysell M. Mortimer (2014)
Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins.
J. Schnitzer (1994)
10.1016/j.jconrel.2011.11.028
Clinical impact of serum proteins on drug delivery.
F. Kratz (2012)
10.1039/c4cc03632h
An Escherichia coli trap in human serum albumin microtubes.
S. Yuge (2014)
10.1016/j.biomaterials.2014.07.062
An albumin-based theranostic nano-agent for dual-modal imaging guided photothermal therapy to inhibit lymphatic metastasis of cancer post surgery.
Qian Chen (2014)
10.1039/C4TB00015C
Graphene quantum dots conjugated albumin nanoparticles for targeted drug delivery and imaging of pancreatic cancer.
P. Nigam (2014)
10.1021/ic500238s
Tetranuclear gadolinium(III) porphyrin complex as a theranostic agent for multimodal imaging and photodynamic therapy.
J. Luo (2014)
10.7150/thno.4571
Unique Diagnostic and Therapeutic Roles of Porphyrins and Phthalocyanines in Photodynamic Therapy, Imaging and Theranostics
L. B. Josefsen (2012)
10.1039/C4MD00200H
Paclitaxel loaded human serum albumin nanoparticles stabilized with intermolecular disulfide bonds
Shufang Zhao (2014)
10.1021/ja909570v
pH-Responsive quantum dots via an albumin polymer surface coating.
Y. Wu (2010)
10.1039/c3cs60376h
Protein micro- and nano-capsules for biomedical applications.
Ulyana Shimanovich (2014)
10.1080/10611860701539584
Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines
K. Greish (2007)
10.1021/bc1002295
Targeted albumin-based nanoparticles for delivery of amphipathic drugs.
Rongzuo Xu (2011)
10.1021/nn1021007
Interactions of poly(amidoamine) dendrimers with human serum albumin: binding constants and mechanisms.
J. Giri (2011)
10.1038/ncomms5740
Selective chemical protein modification.
Christopher D Spicer (2014)
10.1016/j.biomaterials.2013.06.066
Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides.
X. Ming (2013)
10.1016/S1359-6349(10)70002-1
Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer
J. Cortés (2010)
10.1039/C2RA22560C
Enzymatic synthesis of antibody-human serum albumin conjugate for targeted drug delivery using tyrosinase from Agaricus bisporus
A. Rollett (2013)
10.1016/S0959-8049(97)86039-X
Phase I-trial of a methotrexate — Albumin conjugate (MTX-HSA) in cancer patients
G. Hartung (1997)
10.1073/pnas.191498798
Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis
H. Nakamura (2001)
10.1016/j.jconrel.2013.08.020
Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells.
S. Gaca (2013)
10.1021/mp4007776
A tumor environment responsive doxorubicin-loaded nanoparticle for targeted cancer therapy.
Q. Zhu (2014)
Self-assembled human serum albumin-coated complexes for gene delivery with improved transfection.
Nan Liu (2012)
10.1016/j.jconrel.2012.04.009
Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery".
E. Mahon (2012)
10.1016/j.jconrel.2011.09.069
Impact of albumin on drug delivery--new applications on the horizon.
B. Elsadek (2012)
10.1039/c4bm00270a
Protein-polymer therapeutics: a macromolecular perspective.
Y. Wu (2015)
10.1152/AJPGI.00286.2005
Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces.
J. Kim (2006)
10.1371/journal.pone.0093323
A Structure-Based Model for Predicting Serum Albumin Binding
Katrina W. Lexa (2014)
10.1111/j.1749-6632.2009.05159.x
Blocking Interleukin‐1 in Rheumatic Diseases
R. Goldbach-Mansky (2009)
10.1021/mp400303w
Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin.
J. Zhou (2013)
10.1002/jbm.b.32826
Synthesis and characterization of Bi2O3/HSA core-shell nanoparticles for X-ray imaging applications.
Hagit Aviv (2013)
10.1016/j.ab.2011.03.035
Determination of the toluene diisocyanate binding sites on human serum albumin by tandem mass spectrometry.
J. Hettick (2011)
10.1073/pnas.1105270108
Binding of blood proteins to carbon nanotubes reduces cytotoxicity
C. Ge (2011)
10.1155/2012/103973
Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications
S. Banerjee (2012)
10.1016/j.ijpharm.2010.10.012
Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy.
Sie Huey Lee (2011)
10.1208/s12249-013-0041-3
Novel Self-assembly Endows Human Serum Albumin Nanoparticles with an Enhanced Antitumor Efficacy
Dawei Ding (2013)
10.1016/j.oraloncology.2012.07.017
Near-infrared fluorescence sentinel lymph node mapping of the oral cavity in head and neck cancer patients.
J. R. van der Vorst (2013)
10.1021/bc3002419
Galactosyl human serum albumin-NMP1 conjugate: a near infrared (NIR)-activatable fluorescence imaging agent to detect peritoneal ovarian cancer metastases.
V. M. Alexander (2012)
10.1016/j.febslet.2005.02.064
N‐terminal glycine‐specific protein conjugation catalyzed by microbial transglutaminase
T. Tanaka (2005)
10.1038/nrd2591
Strategies in the design of nanoparticles for therapeutic applications
Robby A. Petros (2010)
10.2174/138161212799315830
Human serum albumin conjugated biomolecules for cancer molecular imaging.
Meng Yang (2012)
10.1016/j.jconrel.2008.05.010
Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
F. Kratz (2008)
10.1155/MBD.1996.243
Synthesis, Characterization and Solution Chemistry of trans-Indazoliumtetrachlorobis(Indazole)Ruthenate(III), a New Anticancer Ruthenium Complex. IR, UV, NMR, HPLC Investigations and Antitumor Activity. Crystal Structures of trans-1-Methyl-Indazoliumtetrachlorobis-(1-Methylindazole)Ruthenate(III) an
Kari-Georg Lipponer (1996)
10.1016/j.mam.2011.12.002
Human serum albumin: from bench to bedside.
G. Fanali (2012)
10.1016/j.biomaterials.2009.10.011
Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery.
S. Zhang (2010)
10.3109/10611869308996081
Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method.
W. Lin (1993)
10.1517/17425247.2015.993313
Albumin and its application in drug delivery
D. Sleep (2015)
10.1039/c3cc39258a
Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery.
V. Pichler (2013)
10.1016/j.ejmech.2014.03.064
Study of the binding interaction between fluorinated matrix metalloproteinase inhibitors and Human Serum Albumin.
G. Digilio (2014)
10.1038/sj.onc.1206933
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Z. Siddik (2003)
10.1038/sj.cdd.4401189
Tumor necrosis factor signaling
H. Wajant (2003)
10.1016/j.biomaterials.2013.12.046
Protein modified upconversion nanoparticles for imaging-guided combined photothermal and photodynamic therapy.
Q. Chen (2014)
10.2174/15672018113109990050
Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles.
A. Avachat (2014)
10.1021/bc500427g
Human serum albumin-TRAIL conjugate for the treatment of rheumatoid arthritis.
Hyeong Jun Byeon (2014)
10.2174/1389201014666131226112507
Optical image-guided cancer therapy.
Lihong Bu (2013)
10.1039/b917195a
Human serum albumin coated iron oxide nanoparticles for efficient cell labeling.
Jin Y. Xie (2010)
10.1021/jm301648f
X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019)
Alfred A. Hummer (2013)
10.1016/j.biomaterials.2009.05.060
Pharmacokinetics and bone formation by BMP-2 entrapped in polyethylenimine-coated albumin nanoparticles.
S. Zhang (2009)
10.1038/364362B0
Atomic structure and chemistry of human serum albumin
X. M. He (1993)
10.1016/j.biomaterials.2013.12.100
Blood protein coating of gold nanoparticles as potential tool for organ targeting.
M. Schäffler (2014)
10.1021/JP3021497
Role of the Functionalization of the Gold Nanoparticle Surface on the Formation of Bioconjugates with Human Serum Albumin
F. Cañaveras (2012)
10.1016/j.bios.2012.10.068
An electrochemical biosensor based on human serum albumin/graphene oxide/3-aminopropyltriethoxysilane modified ITO electrode for the enantioselective discrimination of D- and L-tryptophan.
Erhan Zor (2013)
10.1248/BPB.35.280
Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice.
T. Zhao (2012)
10.1002/smll.200901158
Effect of surface properties on nanoparticle-cell interactions.
Ayush Verma (2010)
10.1002/anie.201405924
Site-selective labeling of a lysine residue in human serum albumin.
Shigehiro Asano (2014)
10.1002/adhm.201200296
A core-shell albumin copolymer nanotransporter for high capacity loading and two-step release of doxorubicin with enhanced anti-leukemia activity.
Y. Wu (2013)
10.1517/13543784.16.6.855
DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials
F. Kratz (2007)
10.1016/j.biomaterials.2014.04.067
The effect of protein corona composition on the interaction of carbon nanotubes with human blood platelets.
Silvia H. De Paoli (2014)
10.1038/ki.2012.429
A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy.
Azusa Kodama (2013)
10.1016/j.ejps.2012.06.016
Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells.
A. Taheri (2012)
10.1016/S0378-5173(03)00134-0
Optimization of the preparation process for human serum albumin (HSA) nanoparticles.
K. Langer (2003)
10.5936/csbj.201403001
Site-specific Labeling of a Protein Lysine Residue By Novel Kinetic Labeling Combinatorial Libraries
A. Krantz (2014)
10.1002/EJIC.201300419
Unveiling the Interaction of Vanadium Compounds with Human Serum Albumin by Using 1H STD NMR and Computational Docking Studies
David M. Dias (2013)
10.1039/c1nr11224d
Protein-based nanotubes for biomedical applications.
T. Komatsu (2012)
10.1007/s00775-014-1211-9
Interaction of the anticancer gallium(III) complexes of 8-hydroxyquinoline and maltol with human serum proteins
É. A. Enyedy (2014)
10.1021/bm301531c
Dendronized albumin core-shell transporters with high drug loading capacity.
S. L. Kuan (2013)
10.1016/j.jconrel.2011.06.004
Inorganic nanoparticles for cancer imaging and therapy.
Huang-Chiao Huang (2011)
10.1016/j.chembiol.2010.02.008
Protein chemical modification on endogenous amino acids.
Emmanuel Baslé (2010)
10.1016/J.JMB.2005.07.075
Structural basis of the drug-binding specificity of human serum albumin.
J. Ghuman (2005)
10.1016/J.CHERD.2013.11.024
Efficient loading and entrapment of tamoxifen in human serum albumin based nanoparticulate delivery system by a modified desolvation technique
Hasan Kouchakzadeh (2014)
10.1016/j.biomaterials.2011.10.050
Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types.
Sung-Ho Bae (2012)
10.1002/chem.201302671
Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
M. I. Webb (2013)
10.1007/s10637-008-9208-2
INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model
R. Graeser (2008)
10.1021/ja5038269
Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery
Yao-Rong Zheng (2014)
10.1016/j.jconrel.2012.03.020
Doxil®--the first FDA-approved nano-drug: lessons learned.
Y. Barenholz (2012)
10.1093/PROTEIN/12.6.439
Crystal structure of human serum albumin at 2.5 A resolution.
S. Sugio (1999)
10.1021/BI052628Y
Albumin binding to FcRn: distinct from the FcRn-IgG interaction.
C. Chaudhury (2006)
10.1021/BC049859M
Human serum albumin bearing covalently attached iron(II) porphyrins as O2-coordination sites.
Rong-Min Wang (2005)
10.1080/13506120600960882
Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis
Y. Sekijima (2006)
Nanocarriers as an emerging platform for cancer therapy
S. Wise (2007)
10.1021/mp300686g
Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery.
J. Wu (2013)
10.1021/LA000965W
The interaction of amphiphilic propranolol hydrochloride with haemoglobin and albumin in aqueous solution.
J. Ruso (2000)
10.1002/CHIN.200226275
Transferrin/transferrin receptor-mediated drug delivery.
H. Li (2002)
10.1002/adma.201102313
Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers.
Forrest M Kievit (2011)
10.1016/S1567-5769(02)00271-0
Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications.
H. Maeda (2003)
10.1021/nn406425h
Fluorescent drug-loaded, polymeric-based, branched gold nanoshells for localized multimodal therapy and imaging of tumoral cells.
A. Topete (2014)
10.1021/bc200556n
Site-selective lysine modification of native proteins and peptides via kinetically controlled labeling.
Xi Chen (2012)
10.1128/AAC.00976-09
An Albumin-Conjugated Peptide Exhibits Potent Anti-HIV Activity and Long In Vivo Half-Life
D. Xie (2009)
10.1097/CJI.0b013e31816a88f9
A Humanized Tumor Necrosis Factor Receptor 1 (TNFR1)-specific Antagonistic Antibody for Selective Inhibition of Tumor Necrosis Factor (TNF) Action
R. Kontermann (2008)
10.1002/bdd.769
Chemical reactivity of ethyl (6R)‐6‐[N‐(2‐chloro‐4‐fluorophenyl)sulfamoyl]cyclohex‐1‐ene‐1‐carboxylate (TAK‐242) in vitro
Fumihiro Jinno (2011)
10.1021/JM9905864
A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy.
F. Kratz (2000)
10.1016/0167-4838(90)90281-J
Conformational changes of human serum albumin in vivo induced by free fatty acids as studied by Fourier transform infrared spectroscopy.
J. L. Le Gal (1990)
10.1021/mp200006f
HSA coated iron oxide nanoparticles as drug delivery vehicles for cancer therapy.
Qimeng Quan (2011)
10.1021/bm300418r
Convenient approach to polypeptide copolymers derived from native proteins.
Y. Wu (2012)
10.1016/j.jconrel.2013.01.019
DNA delivery with hyperbranched polylysine: a comparative study with linear and dendritic polylysine.
Z. Kadlecová (2013)
10.1007/s12013-011-9201-9
Investigation of siRNA-Loaded Polyethylenimine-Coated Human Serum Albumin Nanoparticle Complexes for the Treatment of Breast Cancer
S. Abbasi (2011)
10.1002/EJIC.201402197
Zn2+‐Responsive Bimodal Magnetic Resonance Imaging and Fluorescence Imaging Agents and Their Interaction with Human Serum Albumin
Ying-qi Xu (2014)
10.1021/la5034959
Concentration-dependent reversible self-oligomerization of serum albumins through intermolecular β-sheet formation.
A. Bhattacharya (2014)
10.1021/JM020276C
Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
F. Kratz (2002)
10.1016/j.jconrel.2011.07.031
Albumin-based nanoparticles as potential controlled release drug delivery systems.
Ahmed O Elzoghby (2012)
10.1039/c3cc38397k
Human serum albumin (HSA) nanoparticles stabilized with intermolecular disulfide bonds.
Wentan Wang (2013)
10.1007/s00418-010-0676-z
Albumin-based nanoparticles as magnetic resonance contrast agents: I. Concept, first syntheses and characterisation
M. Stollenwerk (2010)
10.1074/jbc.M805536200
Albumin-conjugated C34 Peptide HIV-1 Fusion Inhibitor
C. Stoddart (2008)
10.1007/s10930-014-9553-2
Bioactivity of Albumins Bound to Silver Nanoparticles
J. Mariam (2014)
10.1002/BIP.10196
In vitro protein-polysaccharide conjugation: tyrosinase-catalyzed conjugation of gelatin and chitosan.
T. Chen (2002)
10.1021/la5002144
Effect of dendrimer generation on the interactions between human serum albumin and dendrigraft polylysines.
Nicolas Sisavath (2014)
10.1016/0378-5173(84)90046-2
Analysis of albumin microsphere preparation
J. Gallo (1984)
The molecular mechanism of the neutral-to-base transition of human serum albumin. Acid/base titration and proton nuclear magnetic resonance studies on a large peptic and a large tryptic fragment of albumin.
O. J. Bos (1989)
10.1016/j.ejpb.2013.01.013
Human serum albumin-based design of a diflunisal prodrug.
Feng Yang (2013)



This paper is referenced by
10.1016/j.biomaterials.2017.10.030
Albumin-coordinated assembly of clearable platinum nanodots for photo-induced cancer theranostics.
Yong’an Tang (2018)
10.1021/acs.bioconjchem.5b00170
Human transport protein carrier for controlled photoactivation of antitumor prodrug and real-time intracellular tumor imaging.
X. Li (2015)
10.1016/j.biomaterials.2017.04.036
Protein based therapeutic delivery agents: Contemporary developments and challenges.
Liming Yin (2017)
10.1016/j.nano.2019.102058
Drug-binding albumins forming stabilized nanoparticles for efficient anticancer therapy.
Jianxiang Huang (2019)
10.1007/s12039-019-1671-0
Protein: a versatile biopolymer for the fabrication of smart materials for drug delivery
B. Singh (2019)
10.1016/J.SNB.2017.08.142
Two-step separation-free quantitative detection of HSA and FIB in human blood plasma by a pentaphenylpyyrrole derivative with aggregation-enhanced emission properties
Didi Chen (2018)
10.1155/2017/5462087
Prognostic Significance of Blood Transfusion in Newly Diagnosed Multiple Myeloma Patients without Autologous Hematopoietic Stem Cell Transplantation
Li-ping Fan (2017)
10.1021/ACSAMI.6B08542
ε-Caprolactone-Modified Polyethylenimine as Efficient Nanocarriers for siRNA Delivery in Vivo.
L. Xie (2016)
10.1016/j.saa.2019.117318
Twisted intramolecular charge transfer (TICT) based fluorescent probe for lighting up serum albumin with high sensitivity in physiological conditions.
P. Zhang (2019)
10.1016/j.bmc.2015.09.043
Design of protein homocystamides with enhanced tumor uptake properties for (19)F magnetic resonance imaging.
A. Chubarov (2015)
10.7150/thno.32715
Rod-shape MSN@MoS2 Nanoplatform for FL/MSOT/CT Imaging-Guided Photothermal and Photodynamic Therapy
Lifang Yang (2019)
10.1016/j.copbio.2015.07.005
'Smartening' anticancer therapeutic nanosystems using biomolecules.
Rebeca Núñez-Lozano (2015)
10.1016/j.jinorgbio.2017.04.002
Design an anticancer copper(II) pro-drug based on the flexible IIA subdomain of human serum albumin.
Y. Zhang (2017)
10.1016/j.ijbiomac.2018.03.085
Redox responsive curcumin-loaded human serum albumin nanoparticles: Preparation, characterization and in vitro evaluation.
Tayebeh Saleh (2018)
10.1016/j.bioorg.2018.10.032
Preparation, characterization and in vitro activity of a docetaxel-albumin conjugate.
J. Gao (2019)
10.1021/acs.jmedchem.6b00509
Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain.
Jinxu Qi (2016)
10.1021/acs.chemrev.6b00832
Commercial Applications for Enzyme-Mediated Protein Conjugation: New Developments in Enzymatic Processes to Deliver Functionalized Proteins on the Commercial Scale.
Erika M Milczek (2018)
10.1016/j.bmcl.2017.12.061
Biotin-decorated anti-cancer nucleotide theranostic conjugate of human serum albumin: Where the seed meets the soil?
T. Popova (2018)
10.3389/fbioe.2020.00765
Albumin-Modified Melanin-Silica Hybrid Nanoparticles Target Breast Cancer Cells via a SPARC-Dependent Mechanism
Gennaro Sanità (2020)
10.1016/j.colsurfb.2018.05.014
Molecular interaction studies of some Co(III)-surfactants with the transport protein.
G. Vignesh (2018)
10.1016/j.bmcl.2017.05.084
Multifunctional human serum albumin-therapeutic nucleotide conjugate with redox and pH-sensitive drug release mechanism for cancer theranostics.
Vladimir A Lisitskiy (2017)
10.1186/s11671-017-2206-6
Resveratrol-Loaded Albumin Nanoparticles with Prolonged Blood Circulation and Improved Biocompatibility for Highly Effective Targeted Pancreatic Tumor Therapy
T. Geng (2017)
10.1038/sigtrans.2017.15
Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
H. Zhang (2017)
10.1039/c7bm00425g
Overcoming T. gondii infection and intracellular protein nanocapsules as biomaterials for ultrasonically controlled drug release.
M. Aw (2017)
10.1016/J.CCR.2016.12.016
Development of the application of speciation in chemistry
T. Kiss (2017)
10.1016/j.jinorgbio.2016.06.025
Anticancer activity of Ru- and Os(arene) compounds of a maleimide-functionalized bioactive pyridinecarbothioamide ligand.
M. Hanif (2016)
10.1016/j.msec.2017.08.004
Albumin based versatile multifunctional nanocarriers for cancer therapy: Fabrication, surface modification, multimodal therapeutics and imaging approaches.
Ritu R. Kudarha (2017)
10.1155/2018/6742646
Prognostic Significance of Blood Transfusion in Elderly Patients with Primary Diffuse Large B-Cell Lymphoma
Li-ping Fan (2018)
10.1021/acs.molpharmaceut.5b00938
Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain.
Jinxu Qi (2016)
10.1039/c6sc01536k
Recyclable Cu(i)/melanin dots for cycloaddition, bioconjugation and cell labelling† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c6sc01536k
Y. Sun (2016)
10.3390/COATINGS9070454
Surface Modification of Hemoglobin-Based Oxygen Carriers Reduces Recognition by Haptoglobin, Immunoglobulin, and Hemoglobin Antibodies
Ausanai Prapan (2019)
10.1016/j.inoche.2020.107810
Exploring the structure of a ruthenium acetate cluster for biological purposes
C. F. Silva (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar